Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_4
1
33%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(1)
Other(2)

Detailed Status

unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

terminated133%
unknown267%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_3

Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression

NCT02178683
terminatedphase_4

Bayesian Dose Adjustment of Immunosuppressants After Lung Transplantation

NCT00975663
unknownphase_2

Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor

NCT00304720

Clinical Trials (3)

Showing 3 of 3 trials
NCT02178683Phase 3

Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression

Unknown
NCT00975663Phase 4

Bayesian Dose Adjustment of Immunosuppressants After Lung Transplantation

Terminated
NCT00304720Phase 2

Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3